Back to Search
Start Over
The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal
- Source :
- Oncotarget
- Publication Year :
- 2014
- Publisher :
- Impact Journals LLC, 2014.
-
Abstract
- // Cathy Eng 1 , George J. Chang 2 , Y. Nancy You 2 , Prajnan Das 3 , Miguel Rodriguez-Bigas 2 , Yan Xing 2 , Jean-Nicolas Vauthey 2 , Jane E. Rogers 4 , Aki Ohinata 1 , Priyanka Pathak 1 , Salil Sethi 1 , Jonathan K. Phillips 1 , Christopher H. Crane 3 , Robert A. Wolff 1 1 Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030 2 Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030 3 Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030 4 Division of Pharmacy, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030 Correspondence to: Cathy Eng, e-mail: ceng@mdanderson.org Received: October 01, 2014 Accepted: October 02, 2014 Published: November 14, 2014 ABSTRACT Metastatic squamous cell carcinoma (SCCA) of the anal canal is a rare malignancy for which no standard treatment algorithm exists. To determine the best approach, all patients diagnosed with metastatic SCCA of the anal canal treated at a single institution were evaluated for choice of chemotherapy and treatment outcome. A retrospective study from January 2000 to May 2012 was conducted. Electronic medical records were reviewed for diagnosis of metastatic SCCA of the anal canal. All patients were treatment naive for metastatic disease and completed all radiographic imaging at our institution. The purpose of this study was to evaluate outcomes among patients who received systemic chemotherapy and if appropriate were referred for multidisciplinary intervention (e.g., surgery, radiofrequency ablation, etc.). Seventy-seven patients fulfilled eligibility criteria. Forty-two patients (55%) received 5-fluorouracil (5-FU) + cisplatin (PF); 24 patients (31%) received carboplatin + paclitaxel (CP); 11 patients (14%) received an alternative regimen. After a median follow-up of 42 months, the median progression-free survival (PFS) for all patients was 7 months; the median overall survival (OS) was 22 months. Thirty-three patients (43%) underwent multidisciplinary management for metastatic disease resulting in a median PFS of 16 months (95% CI: 9·2 -22·8) and median OS of 53 months (95% CI: 28·3 – 77·6). Systemic chemotherapy provides durable survival for patients with surgically unresectable metastatic SCCA of the anal canal. Multidisciplinary management for select patients with metastatic disease effectively improves survival and should be considered whenever possible.
- Subjects :
- Adult
Male
medicine.medical_specialty
Palliative care
Paclitaxel
Polyurethanes
Disease-Free Survival
Carboplatin
chemistry.chemical_compound
Surgical oncology
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
Neoplasm Metastasis
Aged
Retrospective Studies
Aged, 80 and over
business.industry
Standard treatment
Palliative Care
Cancer
Retrospective cohort study
Anal canal
Middle Aged
medicine.disease
Anus Neoplasms
Combined Modality Therapy
Surgery
Regimen
medicine.anatomical_structure
Treatment Outcome
Oncology
chemistry
Carcinoma, Squamous Cell
Female
Fluorouracil
Clinical Research Paper
Neoplasm Recurrence, Local
business
Subjects
Details
- Language :
- English
- ISSN :
- 19492553
- Volume :
- 5
- Issue :
- 22
- Database :
- OpenAIRE
- Journal :
- Oncotarget
- Accession number :
- edsair.doi.dedup.....f5bfbd12b920fff5a5667c76ed757521